Parametric experimental tests of steam gasification of pine wood in a fluidized bed reactor

Among Renewable Energy Sources (RES), biomass represent one of the most common and suitable solution in order to contribute to the global energy supply and to reduce greenhouse gases (GHG) emissions. The disposal of some residual biomass, as pruning from pine trees, represent a problem for agricultural and agro-industrial sectors. But if the residual biomass are used for energy production can become a resource. The most suitable energy conversion technology for the above-mentioned biomass is gasification process because the high C/N ratio and the low moisture content, obtained from the analysis. In this work a small-pilot bubbling-bed gasification plant has been designed, constructed and used in order to obtain, from the pine trees pruning, a syngas with low tar and char contents and high hydrogen content. The activities showed here are part of the activities carried out in the European 7FP UNIfHY project. In particular the aim of this work is to develop experimental test on a bench scale steam blown fluidized bed biomass gasifier. These tests will be utilized in future works for the simulations of a pilot scale steam fluidized bed gasifier (100 kWth) fed with different biomass feedstock. The results of the tests include produced gas and tar composition as well gas, tar and char yield. Tests on a bench scale reactor (8 cm I.D.) were carried out varying steam to biomass ratio from 0.5, 0.7 and 1 to 830°C

State of Art of Small Scale Biomass Gasification Power Systems: A Review of the Different Typologies

The security of supply and climate change issues and the linked recent growth of the local power generation by means of renewable energies technologies are providing real opportunities for the development of small scale biomass gasification systems. The present paper reports the state of art of the small scale gasification power plants. Initial attention has been given to the different biomass feedstock suitable for gasification, focusing on residues with low cost and low environmental impact. Then the two major typologies of gasifiers (fixed and fluidized bed) have been analyzed in terms of raw gas yield, composition and tar and particulate content. The different cold and hot raw gas conditioning systems, highlighting their compatibility with the different gasification system, are described. High efficiency examples of power production by means of internal combustion engine, micro gas turbine, Solid Oxide Fuel Cell or a mix of them, both as realized plants and process simulated ones, have been then reported. The paper provides an overview of the different power plants in terms of efficiency, reliability and cost. © 2013 The Authors. Published by Elsevier Ltd. Selection and peer-review under responsibility of ATI NAZIONALE

Effect of feed glucose and acetic acid on continuous biohydrogen production by Thermotoga neapolitana

This study focused on the effect of feed glucose and acetic acid on biohydrogen production by Thermotoga neapolitana under continuous-flow conditions. Increasing the feed glucose concentration from 11.1 to 41.6 mM decreased the hydrogen yield from 3.6 (±0.1) to 1.4 (±0.1) mol H2/mol glucose. The hydrogen production rate concomitantly increased until 27.8 mM of feed glucose but remained unaffected when feed glucose was further raised to 41.6 mM. Increasing the acetic acid concentration from 0 to 240 mM hampered dark fermentation in batch bioassays, diminishing the cumulative hydrogen production by 45% and the hydrogen production rate by 57%, but induced no negative effect during continuous operation. Indeed, throughout the continuous flow operation the process performance improved considerably, as indicated by the 47% increase of hydrogen yield up to 3.1 (±0.1) mol H2/mol glucose on day 110 at 27.8 mM feed glucose

HisE11 and HisF8 Provide Bis-histidyl Heme Hexa-coordination in the Globin Domain of Geobacter sulfurreducens Globin-coupled Sensor

Among heme-based sensors, recent phylogenomic and sequence analyses have identified 34 globin coupled sensors (GCS), to which an aerotactic or gene-regulating function has been tentatively ascribed. Here, the structural and biochemical characterization of the globin domain of the GCS from Geobacter sulfurreducens (GsGCS162) is reported. A combination of X-ray crystallography (crystal structure at 1.5 Å resolution), UV-vis and resonance Raman spectroscopy reveals the ferric GsGCS162 as an example of bis-histidyl hexa-coordinated GCS. In contrast to the known hexa-coordinated globins, the distal heme-coordination in ferric GsGCS162 is provided by a His residue unexpectedly located at the E11 topological site. Furthermore, UV-vis and resonance Raman spectroscopy indicated that ferrous deoxygenated GsGCS162 is a penta-/hexa-coordinated mixture, and the heme hexa-to-penta-coordination transition does not represent a rate-limiting step for carbonylation kinetics. Lastly, electron paramagnetic resonance indicates that ferrous nitrosylated GsGCS162 is a penta-coordinated species, where the proximal HisF8-Fe bond is severed. © 2008 Elsevier Ltd. All rights reserved

Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1

TNF receptor-associated protein 1 (TRAP1), the main mitochondrial member of the heat shock protein (HSP) 90 family, is induced in most tumor types and is involved in the regulation of proteostasis in the mitochondria of tumor cells through the control of folding and stability of selective proteins, such as Cyclophilin D and Sorcin. Notably, we have recently demonstrated that TRAP1 also interacts with the regulatory protein particle TBP7 in the endoplasmic reticulum (ER), where it is involved in a further extra-mitochondrial quality control of nuclear-encoded mitochondrial proteins through the regulation of their ubiquitination/degradation. Here we show that TRAP1 is involved in the translational control of cancer cells through an attenuation of global protein synthesis, as evidenced by an inverse correlation between TRAP1 expression and ubiquitination/degradation of nascent stress-protective client proteins. This study demonstrates for the first time that TRAP1 is associated with ribosomes and with several translation factors in colon carcinoma cells and, remarkably, is found co-upregulated with some components of the translational apparatus (eIF4A, eIF4E, eEF1A and eEF1G) in human colorectal cancers, with potential new opportunities for therapeutic intervention in humans. Moreover, TRAP1 regulates the rate of protein synthesis through the eIF2α pathway either under basal conditions or under stress, favoring the activation of GCN2 and PERK kinases, with consequent phosphorylation of eIF2α and attenuation of cap-dependent translation. This enhances the synthesis of selective stress-responsive proteins, such as the transcription factor ATF4 and its downstream effectors BiP/Grp78, and the cystine antiporter system xCT, thereby providing protection against ER stress, oxidative damage and nutrient deprivation. Accordingly, TRAP1 silencing sensitizes cells to apoptosis induced by novel antitumoral drugs that inhibit cap-dependent translation, such as ribavirin or 4EGI-1, and reduces the ability of cells to migrate through the pores of transwell filters. These new findings target the TRAP1 network in the development of novel anti-cancer strategies

TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma

Colorectal carcinoma (CRC) is a common cause of cancer-related death worldwide. Indeed, treatment failures are triggered by cancer stem cells (CSCs) that give rise to tumor repopulation upon initial remission. Thus, the role of the heat shock protein TRAP1 in stemness was investigated in CRC cell lines and human specimens, based on its involvement in colorectal carcinogenesis, through regulation of apoptosis, protein homeostasis and bioenergetics. Strikingly, co-expression between TRAP1 and stem cell markers was observed in stem cells located at the bottom of intestinal crypts and in CSCs sorted from CRC cell lines. Noteworthy, TRAP1 knockdown reduced the expression of stem cell markers and impaired colony formation, being the CSC phenotype and the anchorage-independent growth conserved in TRAP1-rich cancer cells. Consistently, the gene expression profiling of HCT116 cells showed that TRAP1 silencing results in the loss of the stem-like signature with acquisition of a more-differentiated phenotype and the downregulation of genes encoding for activating ligands and target proteins of Wnt/β-catenin pathway. Mechanistically, TRAP1 maintenance of stemness is mediated by the regulation of Wnt/β-catenin signaling, through the modulation of the expression of frizzled receptor ligands and the control of β-catenin ubiquitination/phosphorylation. Remarkably, TRAP1 is associated with higher expression of β-catenin and several Wnt/β-catenin target genes in human CRCs, thus supporting the relevance of TRAP1 regulation of β-catenin in human pathology. This study is the first demonstration that TRAP1 regulates stemness and Wnt/β-catenin pathway in CRC and provides novel landmarks in cancer biology and therapeutics

Immunotherapy with CAR-T cells in paediatric haematology-oncology

Despite being a rare disease, cancer is the first cause of mortality due to disease during the paediatric age in the developed countries. The current, great increase in new treatments, such as immunotherapy, constitutes a new clinical and regulatory paradigm. Cellular immunotherapy is one of these types of immunotherapy. In particular, the advanced therapy drugs with chimeric antigen receptors in the T-lymphocytes (CAR-T), and particularly the CAR-T19 cells, has opened up a new scenario in the approach to haematology tumours like acute lymphoblastic leukaemia and the B-Cell lymphomas. The approval of tisagenlecleucel and axicabtagene ciloleucel by the regulatory authorities has led to the setting up of the National Plan for Advanced Therapies-CAR-T drugs in Spain. There is evidence of, not only the advantage of identifying the centres most suitable for their administration, but also the need for these to undergo a profound change in order that their healthcare activity is extended, in some cases, to the ability for the in-house manufacture of these types of therapies. The hospitals specialised in paediatric haematology-oncology thus have the challenge of progressing towards a healthcare model that integrates cellular immunotherapy, having the appropriate capacity to manage all aspects relative to their use, manufacture, and administration of these new treatments.A pesar de ser una enfermedad rara, el cáncer es la primera causa de mortalidad por enfermedad durante la edad pediátrica en los países desarrollados. En este momento, la irrupción de nuevos tratamientos como la inmunoterapia constituye un nuevo paradigma clínico y regulatorio. Uno de estos tipos de inmunoterapia es la inmunoterapia celular. En particular, los medicamentos de terapia avanzada con receptores antigénicos quiméricos en los linfocitos T (CAR-T), y en concreto las células CAR-T19, han supuesto un nuevo escenario en el abordaje de los tumores hematológicos, como la leucemia aguda linfoblástica y los linfomas de células tipo B. La aprobación por las autoridades regulatorias de tisagenlecleucel y axicabtagene ciloleucel,ha impulsado la puesta en marcha del Plan Nacional de Terapias Avanzadas-Medicamentos CAR-T en España, evidenciándose no solo la conveniencia de identificar los centros más adecuados para su administración, sino la necesidad de que estos sufran una profunda transformación para que su actividad asistencial se extienda en algunos casos a la capacidad de fabricación propia de este tipo de terapias. Los hospitales especializados en hematooncología pediátrica tienen por tanto el reto de evolucionar hacia un modelo asistencial que integre la inmunoterapia celular,dotándose de capacidad propia para gestionar todos los aspectos relativos al uso, fabricación y administración de estos nuevos tratamientos.Fundación CRIS contra el cáncer